BATwire Implant Kit

Inclusion Criteria:

Age at least 21 years and no more than 80 years at the time of enrollment.

Appropriate candidate for the surgery as determined by an evaluation from the implanting physician using a carotid duplex ultrasound (CDU) and/or a computed tomography angiography (CTA), and a review of medical history (including existence of infections that may increase implant risk). Evaluation must confirm the following within 45 days of the Barostim implant (60 days allowed if a proctor is required):

Appropriate medical condition and medical history for implantation of the Barostim System AND
Anatomy that enables this implant procedure, with no vascular structures or orientations or neck anomalies that would be obstructive to the implantation path AND

The artery planned for the Barostim implant must have:

A carotid bifurcation below the level of the mandible AND
No ulcerative carotid arterial plaques AND
No carotid atherosclerosis producing a 30% or greater reduction in linear diameter in the internal carotid AND
No carotid atherosclerosis producing a 30% or greater reduction in linear diameter in the distal common carotid AND
Have had no prior surgery, radiation, or endovascular stent placement in the carotid artery or the carotid sinus region AND
Able to discontinue the use of antiplatelet drugs (e.g., aspirin) in advance of the procedure, if required.
Six-minute hall walk (6MHW) ≥ 150 m AND ≤ 400 m within 45 days prior to implant (60 days allowed if a proctor is required).
Serum estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m^2 using the CKD-EPI method within 45 days prior to the Barostim implant (60 days allowed if a proctor is required).
Body mass index ≤ 40 kg/m^2 within 45 days prior to the Barostim implant (60 days allowed if a proctor is required).
If female and of childbearing potential, must use a medically accepted method of birth control (e.g., barrier method with spermicide, oral contraceptive, or abstinence) and agree to continue use of this method for the duration of the study. Women of childbearing potential must have a negative pregnancy test within 14 days prior to the Barostim implant.
Subjects implanted with a cardiac rhythm management device that does not utilize an intracardiac lead, or implanted with a neurostimulation device, must be approved by the CVRx Clinical department.
At the end of screening and baseline, the subject still meets the Barostim Indication for Use
Signed a CVRx-approved informed consent form for participation in this study.

Exclusion Criteria:

Received cardiac resynchronization therapy (CRT) within six months of enrollment, or is actively receiving CRT.

Any of the following contraindications:

Baroreflex failure or autonomic neuropathy
Uncontrolled, symptomatic cardiac bradyarrhythmias
Known allergy to silicone or titanium
Unstable ventricular arrhythmias.
Presence of baseline cranial nerve dysfunction at risk from cervical interventions on the carotid bifurcation determined by the Ear, Nose and Throat (ENT) examination.
Subjects with any surgery that has occurred, or is planned to occur, within 45 days of the Barostim implant.
Recent history (within 6 months of implant) of significant and uncontrolled bleeding.
Known and untreated hypercoagulability state.

An inappropriate study candidate as evidenced by:

Solid organ or hematologic transplant, or currently being evaluated for an organ transplant.
Has received or is receiving LVAD therapy or chronic dialysis.
Current or planned treatment with intravenous positive inotrope therapy.
Primary pulmonary hypertension.
Severe COPD or severe restrictive lung disease (e.g., requires chronic oral steroid use or home oxygen use).
Heart failure secondary to a reversible cause, such as cardiac structural valvular disease, acute myocarditis and pericardial constriction.
Clinically significant cardiac structural valvular disease.
Unable or unwilling to fulfill the protocol medication compliance and follow-up requirements, for reasons including but not limited to an unresolved history of alcohol or substance abuse or psychiatric disorder.
Active malignancy.
Any other serious medical condition that may adversely affect the safety of the participant or validity of the study, in the opinion of the investigator.
Life expectancy less than one year.

Any of the following within 3 months prior to the Barostim implant.

Myocardial infarction
Unstable angina
Percutaneous coronary intervention (e.g., CABG or PTCA)
Cerebral vascular accident or transient ischemic attack
Sudden cardiac death
Surgical cardiac intervention (e.g., cardiac ablation, valve replacement)
Enrolled and active in another (e.g., device, pharmaceutical, or biological) clinical study unless approved by the CVRx Clinical department.